New Diabetes Device Places 2nd at 2019 RESI Innovation Challenge

BOYDSense, Inc., a medical technology company, is developing a novel handheld device designed to accurately predict blood glucose values.

The company recently returned from the Redefining Early Stage Investments conference in Boston with a second-place finish in the RESI Innovation Challenge and myriad accolades from both investors and attendees at the event, one of the year’s biggest investment conferences for biotech and med-tech.

The company’s g-Sense Breath Meter, a handheld device designed to accurately predict blood glucose values by measuring the volatile organic compounds (VOCs) in human breath, was selected as a finalist and ultimately a winner from among 130 entries

“Being one of the top finishers at this prestigious industry event confirms what our leadership team and current investors already know—that BOYDSense’s technology is poised to play a pivotal role in the transition to non-invasive monitoring of diabetes and other chronic conditions,” said BOYDSense CEO Bruno Thuillier.

BOYDSense was among 350 biotech startups and 350 investors that attended the annual event, which was organized by Life Science Nation.

“Both the second-place award from the RESI Innovation Challenge itself and the enthusiasm we received from investors and peers significantly boosted the momentum BOYDSense needs to continue on the path to bringing our first commercial product to market and into the hands of people with diabetes,” Thuillier added.